钆基对比剂给药后脑内钆潴留的神经学效应
该研究于2017年3月至2018年7月对183只雄性Wistar大鼠给予20次静脉注射多种钆基对比剂或生理盐水,在注射后6周和34周进行行为学测试及组织学、质谱分析。结果显示各对比剂组与对照组在任何行为学测试中均无差异(P=.08至P=.99),线性对比剂脑内钆浓度高于大环类,钆清除率因对比剂而异,未观察到神经毒性临床证据。
要点
- 大鼠接受超诊断剂量钆基对比剂后,6周和34周行为学测试与对照组无差异(P=.08至P=.99)。
- 线性对比剂在基底节和齿状核的钆浓度高于大环类(P<.001)。
- 钆布醇清除率最大(基底节中位数62%,齿状核70%),钆双胺无实质清除。
核心结论
- 在该大鼠模型中,给予超诊断剂量的线性和大环类钆基对比剂后未观察到神经毒性的临床证据。
研究设计与样本
- 动物实验,183只雄性Wistar大鼠,2017年3月至2018年7月给予20次静脉注射2.5 mmol/kg体重(相当于80个人类等效剂量)的多种钆基对比剂或生理盐水,注射后6周和34周行五项行为学测试及电感耦合等离子体质谱、透射电镜和组织病理学检查。
关键影像表现/征象
- 透射电镜在线性对比剂暴露的脑组织中检测到钆灶,但任何对比剂均未观察到组织病理学差异。
- 线性对比剂暴露大鼠在6周和34周时基底节和齿状核的钆浓度均高于大环类对比剂暴露大鼠(P<.001)。
- 34周时钆双胺、钆贝酸、钆特酸和钆布醇暴露大鼠的脑脊液和血清中钆大部分清除,脑脊液清除范围70%-98%,血清清除范围34%-94%,尿液中几乎完全清除(清除范围96%-99%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Concerns over the neurotoxic potential of retained gadolinium in brain tissues after intravenous gadolinium-based contrast agent (GBCA) administration have led to pronounced worldwide use changes, yet the clinical sequelae of gadolinium retention remain undefined. Purpose To assess clinical and neurologic effects and potential neurotoxicity of gadolinium retention in rats after administration of various GBCAs. Materials and Methods From March 2017 through July 2018, 183 male Wistar rats received 20 intravenous injections of 2.5 mmol per kilogram of body weight (80 human equivalent doses) of various GBCAs (gadodiamide, gadobenate, gadopentetate, gadoxetate, gadobutrol, gadoterate, and gadoteridol) or saline over 4 weeks. Rats were evaluated 6 and 34 weeks after injection with five behavioral tests, and inductively coupled plasma mass spectrometry, transmission electron microscopy, and histopathology were performed on urine, serum, cerebrospinal fluid (CSF), basal ganglia, dentate nucleus, and kidney samples. Dunnett post hoc test and Wilcoxon rank sum test were used to compare differences between treatment groups. Results No evidence of differences in any behavioral test was observed between GBCA-exposed rats and control animals at either 6 or 34 weeks (P = .08 to P = .99). Gadolinium concentrations in both neuroanatomic locations were higher in linear GBCA-exposed rats than macrocyclic GBCA-exposed rats at 6 and 34 weeks (P < .001). Gadolinium clearance over time varied among GBCAs, with gadobutrol having the largest clearance (median: 62% for basal ganglia, 70% for dentate) and gadodiamide having no substantial clearance. At 34 weeks, gadolinium was largely cleared from the CSF and serum of gadodiamide-, gadobenate-, gadoterate-, and gadobutrol-exposed rats, especially for the macrocyclic agents (range: 70%-98% removal for CSF, 34%-94% removal for serum), and was nearly completely removed from urine (range: 96%-99% removal). Transmission electron microscopy was used to detect gadolinium foci in linear GBCA-exposed brain tissue, but no histopathologic differences were observed for any GBCA. Conclusion In this rat model, no clinical evidence of neurotoxicity was observed after exposure to linear and macrocyclic gadolinium-based contrast agents at supradiagnostic doses. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Ayers-Ringler, McDonald, Connors, et al. Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration. Radiology. 2021. PMID: 34931861. doi:10.1148/radiol.210559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。